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Abstract Genistein is a small, biologically active flavonoid
that is found in high amounts in soy. This important
compound possesses a wide variety of biological activities,
butitisbestknownforitsabilitytoinhibitcancerprogression.
In particular, genistein has emerged as an important inhibitor
of cancer metastasis. Consumption of genistein in the diet has
been linked to decreased rates of metastatic cancer in a
number of population-based studies. Extensive investigations
have been performed to determine the molecular mechanisms
underlying genistein’s antimetastatic activity, with results
indicating that this small molecule has significant inhibitory
activity at nearly every step of the metastatic cascade. Reports
have demonstrated that, at high concentrations, genistein can
inhibit several proteins involved with primary tumor growth
and apoptosis, including the cyclin class of cell cycle
regulators and the Akt family of proteins. At lower concen-
trations that are similar to those achieved through dietary
consumption,genisteincaninhibittheprometastaticprocesses
of cancer cell detachment, migration, and invasion through a
variety of mechanisms, including the transforming growth
factor (TGF)-β signaling pathway. Several in vitro findings
have been corroborated in both in vivo animal studies and in
early-phase human clinical trials, demonstrating that genis-
tein can both inhibit human cancer metastasis and also
modulate markers of metastatic potential in humans, respec-
tively. Herein, we discuss the variety of mechanisms by
which genistein regulates individual steps of the metastatic
cascade and highlight the potential of this natural product as
a promising therapeutic inhibitor of metastasis.
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1 Introduction
Genistein, or 4′,5,7-trihydroxyisoflavone, is a small mole-
cule found in high natural abundance in soy products [1].
Individuals who consume soy as a dietary staple have
elevated blood concentrations of genistein when compared
to those who consume a Western-style red-meat-based diet
[2]. This difference in genistein concentrations has been
associated with differential outcomes in a variety of clinical
contexts including cholesterol regulation, osteoporosis, and
cancer. Interest in genistein as a potential therapeutic agent
has recently risen in the field of oncology as population-
based studies have linked genistein consumption with a
decreased risk of mortality from several types of cancer,
most notably prostate and breast cancer [3–9]. This
important small molecule possesses a relatively wide array
of biological activities that may underlie its ability to
reduce the mortality associated with various cancer types.
In particular, several studies have indicated that inhibition
of metastasis by genistein represents an important mecha-
nism by which it is able to reduce mortality associated with
solid organ cancer. This is highly relevant, as solid organ
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to the metastatic stage. Genistein has therefore become one of
the most widely studied small-molecule inhibitors of both
cancer cell growth and metastasis and has the potential to be
of substantial clinical benefit to patients with various types of
cancer.
This article will review the structural, pharmacologic, and
biological characteristics of genistein that are relevant to its
ability to inhibit metastasis of various cancer types. We will
describe the structural characteristics of genistein and its
related isoflavone family members and will demonstrate how
these structural features confer biological activity onto this
small molecule. In addition, we will discuss genistein’s
pharmacologic characteristics in relation to epidemiological
studies, which provide one measure of genistein’sa n t i m e t a -
static activity. The main focus of this article will be on
genistein’sabilitytoregulateindividualsteps ofthe metastatic
cascade, including cell proliferation, cell detachment, cell
migration, and cell invasion. Finally, preclinical models of
metastasis, as well as prospective human studies of pharma-
cology, toxicity, and efficacy, will be discussed.
2 Genistein: structure and epidemiology
2.1 Structural characteristic and synthesis of genistein
Genistein was originally isolated by Perkin and Newbury in
1899 from Dyer’s Broom (Genista tinctoria)[ 10]. This
naturally derived compound is a member of the isoflavone
branch of the flavonoid family of small molecules, which
includes over 5,000 compounds [11, 12]. The isoflavones
are structurally characterized by their 3-phenylchromen-4-
one backbone, which consists of two benzene rings linked by
a heterocyclic pyran ring. In addition to this heterocyclic core,
genistein and its related isoflavone family members are
polyphenols, in that they contain several hydroxyl groups
attached to core phenyl rings. These phenols lend significant
antioxidant activity to this class of compounds, with genistein
and other related flavonoids, such as epigallocatechin 3-
gallate possessing significant activity against free radicals in
tissue [11]. Importantly, genistein is a recognized protein-
tyrosine kinase inhibitor [13]. Although this has not been
proven, this activity is presumed to stem from genistein’sC 4 ′
phenolic group (Fig. 1), which structurally resembles the
phosphoacceptor moiety of tyrosine.
Genistein’s structural characteristics also impart this
compound with the ability to act as a weak estrogen mimic,
leading to its classification as a phytoestrogen (i.e., an
estrogen-like compound derived from a plant source) [14].
In particular, compared to 17-β-estradiol, the predominant
sex hormone present in females, genistein shares both a near
identical molecular weight as well as a similar hydroxylation
pattern, with two key phenolic groups at C7 and C4′ (Fig. 1)
[15]. Importantly, the C7 hydroxyl group is needed for
genistein to bind to the estrogen receptor (ER), as it mimics
the A ring of the steroidal estrogen core. Furthermore, the
distance (∼11.5 Å) between the C7 and C4′ phenolic groups
(highlighted in green, see Fig. 1) allows for optimal binding
of genistein to the ER, as they are in very similar positions to
the key hydroxyl groups on the estradiol core [11]. Both the
C4′ a n dC 7p h e n o l i cg r o u p sh a v eb e e ns h o w ni nac r y s t a l
structure to form key contacts with ERβ,w i t ht h eC 4 ′
phenol binding to Glu305 and Arg306 and the C7 phenol to
His475 [16]. Because of these structural characteristics,
genistein can bind to both α and β isoforms of the ER
[17, 18], although it binds to ERβ with 20-fold higher
affinity than ERα [19]. Genistein’s ability to both bind and
stimulate the ER has led to several studies on its effects in
postmenopausal women, with results suggesting that genis-
tein could restore bone mass and relieve menopausal
symptoms such as hot flashes and vaginitis [11]. Therefore,
the structural similarities between genistein and estradiol
have important functional consequences, which could lead to
improvements in overall health or potentially detrimental
side effects.
Due to the various biological activities that are associated
with genistein, material for further clinical studies is in high
demand. Although genistein and its related isoflavone family
member, daidzein, are the most prominent isoflavones found
in soy products, concentrations of these small molecules are
usuallyquitelowandcanvarydependinguponthetypeofsoy
preparation, making extraction from the natural source
inefficient. Efforts have been made to increase the concen-
trations of genistein and other isoflavones in other plant
products,suchascornandtobacco[20, 21], but this approach
currently remains a challenge. Therefore, in addition to
obtaining genistein from natural sources, several synthetic
methods have also been developed in an effort to generate
more material for biological analysis.
The first synthesis of genistein was in 1928 by Baker
and Robinson, in which they employed a one-carbon
homologation of a deoxybenzoin substrate to obtain the 2-
OH
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Fig. 1 Structures of genistein (left)a n d1 7 - β-estradiol (right).
Genistein’s structure is characterized by a 3-phenylchromen-4-one
core (highlighted in red) and phenolic substitution at the C4′, C5, and
C7 positions. The C4′ and C7 phenols of genistein are in very similar
positions to key hydroxyl groups on estradiol (highlighted in green),
allowing genistein to bind to the ER
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hydroxyphenyl benzyl ketone) route still remains one of the
most prominent routes that is used to generate isoflavones,
along with the closely related chalcone route (Fig. 2a, b)
[15]. In the deoxybenzoin route, the deoxybenzoin substrate
is constructed under Lewis acidic conditions by condensation
of a free phenol with a reagent containing an electrophilic
carboxylic acid (Friedel-Crafts reaction). Treatment of this
deoxybenzoin substrate with an activated one-carbon donor
(e.g., N,N-DMF dimethyl acetal or DMF/PCl5)t h e nl e a d st o
formation of the pyran ring to generate the desired isoflavone
[23–25]. In the chalcone route, a chalcone substrate is
generated by an aldol reaction between an appropriate
acetophenoneandanaromaticaldehyde.Oxidative rearrange-
ment of the chalcone substrate by utilizing either a thallium
(III) or hypervalent iodide reagent in methanol, followed by
base-mediated ring closure, yields the final desired products
[26]. Although these two routes are used to construct bulk
quantities of synthetic genistein, other methods such as the
Suzuki-Miyaura cross-coupling of arylboronic acids and
halochromones are often used to generate smaller amounts
of material for biological analysis [27, 28].
2.2 Dietary consumption and epidemiology of genistein
Although genistein can be synthetically produced to increase
the supply of this natural product, humans most often ingest
genistein through dietary consumption of soy products.
Estimates of average daily genistein consumption by individ-
uals who consume a soy-based diet range from 0.3 to 1.0 mg
genistein per kilogram body weight per day [29–41]. The
primary chemicalformpresent insoybeansand nonfermented
soy products is the C7-glycosylated form, also known as
genistin [42]. After ingestion of genistin, hydrolysis within
the intestine yields the aglycone, genistein, and the free
sugar [43]. Rodent-based pharmacologic studies demonstrate
that, after absorption from the intestine, genistein under-
goes first-pass metabolism in the liver, as well as
enterohepatic circulation [44]. These findings are corrob-
orated with preliminary human dietary studies that
demonstrate that ∼90% of the total amount of genistein
in the blood has undergone extensive liver metabolism and
exists in either the glucuronidated or sulfated form [2],
while only 10% exists in the free (i.e., nonconjugated)
form. Though studies investigating the biological activity
Fig. 2 a The deoxybenzoin route for the synthesis of genistein and
other isoflavones. The deoxybenzoin substrate is constructed with a
Friedel-Crafts reaction between a substituted phenol and a phenyl-
acetic acid derivative. A one-carbon homologation then completes the
synthesis of the isoflavone core. b The chalcone route for isoflavone
synthesis. The chalcone substrate is obtained from an aldol reaction
between an acetophenone and an aromatic aldehyde. Oxidative
rearrangement with diacetoxyiodo benzene or thallium(III) nitrate in
MeOH then provides the intermediate acetal, which cyclizes to the
isoflavone under base-catalyzed conditions
Cancer Metastasis Rev (2010) 29:465–482 467of free genistein compared to its conjugated metabolic
products are limited, it appears that the metabolic products
do not have the same biologic activity [45, 46].
Therefore, it is important to consider that the concentration
of free genistein in the blood of soy consumers is in the low
nanomolar range. Effects found to be induced by genistein in
preclinical model systems at low nanomolar concentrations
therefore represent potentially important mechanisms that
could be operative in humans. However, when considering
effects induced by genistein in preclinical models that require
concentrations in the low-to-mid micromolar range, their
potential clinical relevance becomes less clear. It is clear that
micromolar concentrations of total genistein (i.e., conjugated
plus free forms) can readily be attained in the blood after
high-dose genistein administration (see Section 5). However,
because the majority of total genistein has undergone
metabolic inactivation, its ability to induce a pharmacologic
effect is questionable. On the other hand, some animal
studies (see Section 4) appear to suggest that effects
requiring high concentrations in vitro may be operative in
vivo at lower concentrations.
Dietary studies of soy consumption provide a measure of
the steady-state blood concentrations of genistein in humans
after chronic exposure. The blood concentrations of the free
and conjugated forms of genistein are 100 to 1,000 times
lower in low-soy consumers (i.e., those who subsist on a
Western red-meat-based diet) than those found in high-soy
consumers [2]. This increased blood concentration of
genistein in soy consumers has been linked to the differential
clinical outcomes observed between high- and low-soy-
consuming populations. However, it is important to consider
that the differential dietary consumption of genistein occurs
alongside of a much broader spectrum of dietary and
lifestyle differences across populations. These other factors
likely contribute to the different and sometimes conflicting
results of population-based studies. In this review, we will
highlight several investigations that identify positive links
between dietary genistein consumption and cancer reduction.
However, care should be taken to consider additional factors
that may have an impact in these studies.
Population-based studies have linked decreased cancer
incidence to increased genistein consumption for several
cancer types, with most studies focused on prostate or
breast cancer [3–9]. A recent meta-analysis of five cohort
studies and eight case–control studies indicates that there is
aninverserelationshipbetweendietarygenisteinconsumption
and prostate cancer incidence and mortality [6]. Age-adjusted
rates of metastatic prostate cancer are approximately tenfold
lower among high-soy-consuming Southeast Asians than
amonglow-soyconsumersintheWest(i.e.,USAandWestern
Europe) [3–5]. However, after migration of Southeast Asians
to the West, immigrant risk of prostate cancer approaches
that of Western populations within one generation, indicating
that differences in prostate cancer incidence are not entirely
genetic and that they can be pharmacologically altered.
Interestingly, the rates of localized or early-stage prostate
cancer appear to be similar across different populations. The
prevalence of primary prostate cancer in Chinese men that
were born in China is only slightly lower than of American-
born Chinese men (i.e., twofold lower of equal) [3, 47].
Similarly, while the rates of early-stage prostate cancer are
similar between Japanese and American men, death from
metastatic prostate cancer is much higher in men living in the
USA [48]. The increased prevalence of clinical cancer may
occur within a single generation after migration from the
East to West [5]. These data support the notion that dietary
constituents, such as genistein, and/or lifestyle factors may
modulate the metastatic behavior of prostate cancer and
reduce the incidence of more aggressive disease.
Although most of the epidemiological data regarding
genistein’s anticancer activity are focused on prostate cancer,
the effects ofthisnatural product havealsobeenstudied inthe
context of other cancer types. In breast cancer, genistein
consumption has been associated with a decrease in disease
incidence [7, 8], potentially as a result of genistein’s ability
to mimic natural estrogens (see Section 2.1), which are
known to play a role in breast cancer progression. These
studies have not specifically looked at factors related to
the metastatic incidence of breast cancer. Several studies
have also reported an inverse association between genis-
tein consumption and colon cancer risk [9, 49], but these
studies were also focused on the initial development of the
disease as opposed to the progression to metastatic
disease. Taken together, population-based studies have
definitively demonstrated that those who subsist on a soy-
based diet have blood concentrations of genistein much
higher than those who do not. Further, they suggest that
genistein may play a role in initial cancer prevention and/
or in cancer progression. Confounding dietary and lifestyle
factors cannot be excluded and likely contribute to
differences between studies.
3 Genistein’s effects on the metastatic cascade
As detailed in the previous sections, several population-based
epidemiological studies suggest that genistein can inhibit the
developmentofmetastaticdisease ina varietyofcancertypes.
Metastasis is a multistep process wherein a cancer cell leaves
the site of the primary lesion, passes through the circulatory
system, and establishes a secondary tumor at a new distant
organ site. The individual cell-based steps that together
constitute the metastatic cascade are depicted in Fig. 3.T h e
metastatic process begins with the growth of cancer cells at
the primary site of development, followed by decreased cell
adhesion and local invasion through the basement membrane.
468 Cancer Metastasis Rev (2010) 29:465–482The diagnosis of clinical cancer typically requires the
presence of cancer cells that have invaded through the
basement membrane of the primary organ. In contrast, when
cancer cells are present in a clinical tissue specimen but have
not invaded through the basement membrane, it is generally
nottermedcancer.Variousterms havebeenapplied,including
preclinical cancer, intraepithelial cancer, or in situ cancer.
After cells have invaded the basement membrane, their
continued growth and associated induction of angiogenesis
lead to the formation of a primary tumor. Cells then invade
through the stroma of the primary organ, followed by
intravasation into the vessels of the circulatory and lymphatic
systems. Once cells have gained access to the circulatory
system, they are transported to a distant site where they must
attach to the vessel wall and extravasate, thereby entering a
distinctorgan.After invasionand implantationintothe distant
organ, cells resume the process of increased proliferation and
angiogenesis, and begin to form a metastatic tumor. In the
following sections, we will discuss genistein’s ability to
inhibit these various steps of the metastatic cascade in greater
detail. We will begin by describing the various mechanisms
by which genistein can inhibit primary tumor growth,
including its effects on cell proliferation and apoptosis. We
willthendescribegenistein’sabilitytoregulatethelaterstages
of the metastatic process, including cell adhesion, migration,
and invasion.
3.1 Genistein can alter cell proliferation and cell death
In this section, we will discuss genistein’s ability to inhibit
growth of the primary tumor, which is the critical first step
in the progression of metastatic disease. The larger the
primary tumor grows, the more likely that the tumor will be
able to acquire traits that lead to a metastatic phenotype [50].
Increased tumor growth can arise from an increase in the rate
of cell division (i.e., proliferation) and/or a decrease in the
rate of cell death (i.e., apoptosis or programmed cell death).
Genistein can affect both of these processes, as well as
modulate key regulatory protein such as Akt and nuclear
factor κB (NF-κB). In general, low-to-mid micromolar
concentrations of genistein are required for these effects in
cell-culture-based models, though interestingly, effects in
animal models have been observed at lower concentrations.
3.1.1 Effects of genistein on cell cycle progression
The cell cycle is a tightly regulated process, with each step
carefully monitored by a specific group of proteins that act as
checkpoints for proper cell division. The balance between
these key checkpoint proteins is critical for progression
through each step of the cell cycle to occur. The cyclin-
dependentkinase(Cdk)familyofproteinsandtheirassociated
activating cyclins are particularly important regulators of the
cell cycle (reviewed in [51]). For the G1/S-phase transition,
cyclin D-Cdk4/Cdk6, cyclin E-Cdk2, and cyclin A-Cdk2
complexes are necessary for progression through the
checkpoint, while the cyclin B-Cdk1 complex is necessary
for the G2/M-phase transition. Perturbations in the cell cycle,
particularly those that disrupt this Cdk family of proteins,
have a significant impact on the rate of cell division and are
often implicated in the development of primary cancerous
tumors. Therefore, therapeutic modulation of these proteins
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Fig. 3 The metastatic cascade
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development of a variety of cancers.
Several reports have demonstrated that genistein can
induce cell cycle arrest and that it can therapeutically
modulate key regulator cell cycle proteins at concentrations
ranging from 5 to 200 μM[ 52]. It is important to note that
these concentrations are greater than the blood levels that are
observed with dietary consumption, indicating that this is
likely not the primary mechanism by which genistein
inhibits metastasis. However, it is theoretically possible to
achieve these levels in humans, and various animal studies
have also demonstrated that genistein can reduce the primary
tumor size in certain contexts (see Section 4). Therefore,
genistein’s effects on the cell cycle are potentially relevant to
its ability to modulate the ultimate development of metastasis
in humans.
Although several studies have described genistein’s
ability to induce cell cycle inhibition, an exact mechanism
of action has not been identified. Most studies indicate that
genistein potentially targets proteins involved in the G2/M
checkpoint, as it has been shown to induce arrest in this
checkpoint in breast cancer [53–55], prostate cancer [54],
and other cancers [55–57]. The main regulator of the G2/M
checkpoint is Cdc2, also known as Cdk1. In ovarian and
neuroblastoma cancer cells, genistein activates Chk1 and
Chk2, which in turn activate, or dephosphorylate, Cdc25C
and Cdc25A [56, 58]. The Cdc25 proteins are phosphatases
that activate Cdc2; therefore, their inactivation by genistein
thereby inactivates Cdc2 and induces G2/M-phase arrest.
An additional regulator of the G2/M checkpoint is cyclin
B1, which spikes at the G2/M transition, resulting in
progression through this checkpoint. Genistein decreases
cyclin B1 in breast cancer cells, which prevents cells from
passing through this checkpoint and entering mitosis [59].
These combined effects of genistein on Cdc2, cyclin B1, as
well as other cell cycle proteins, all serve to decrease cancer
cell proliferation and therefore represent potential therapeutic
targets.
3.1.2 The effect of genistein on apoptosis
In addition to inhibiting cellular proliferation, genistein also
increases the rateofcancercelldeath.Programmed celldeath,
or apoptosis, is a carefully regulated process that can be
induced by a variety of stimuli, including programmed tissue
remodeling, cell detachment (when it is then termed anoikis),
genomic damage, hypoxia, signaling pathway derangement,
growth factor or cytokine limitations, and infection [60–62].
Dysregulation of apoptosis contributes to the development of
cancer, as decreased rates of cell death facilitate an overall
increase in cell number. For this reason, the apoptotic
pathway, similar to the cell cycle proteins described above,
has been an attractive target for therapeutic development [63].
Genistein can induce apoptosis in a variety of epithelial
cancers [52, 64–66]. These proapoptotic effects occur at
genistein concentrations of 10–200 μM, similar to those
that alter cellular proliferation. Again, as these levels are
higher than the measured blood concentrations of high-soy
consumers, genistein’s ability to inhibit apoptosis may not
be the primary mechanism by which it regulates metastasis.
These mechanisms might still be clinically relevant with
regard to the development of the primary tumor, as these
effects may be of primary importance in the context of
high-dose pharmacologic therapy, in which elevated blood
concentrations of genistein can be obtained.
A major regulator of apoptosis is the Bcl-2 family of
proteins, such as Bcl-2, Bcl-xl, and Bcl-w. These proteins
promote cell survival by sequestering the proapoptotic
proteins Bax and Bak [67, 68]. Antagonizing this reaction
are the BH3-only proteins, which promote apoptosis by
displacing Bax and Bak bound to the Bcl-2 proteins. When
Bax and Bak are released, they oligomerize to the outer
membrane of the mitochondria, providing a channel for
cytochrome c to move into the cytoplasm [69]. Upon release,
cytochrome c interacts with Apaf-1 to bind to procaspase 9,
cleaving this protein to activate caspase 9 [70]. Caspase 9
activation promotes the activation of caspases 3, 6, and 7,
leading to rapid cell death.
Although the exact molecular mechanism of genistein’s
effect on apoptosis has not been identified, most studies
indicate that genistein acts by altering the expression of the
various proapoptotic and antiapoptotic proteins described
above. Specifically, Bcl-xl, an antiapoptotic protein, has been
shown to be decreased in breast cancer [71–73], prostate
cancer [74], and other cancers [75–77] upon treatment with
genistein. Conversely, proapoptotic proteins Bax, caspase 3,
and caspase 9 have all been shown to increase in vitro with
genistein treatment. Increased Bax was observed in breast
cancer [71, 73, 78], prostate cancer [74, 78], and other cancers
[75, 76, 79]. Increased caspase 3 was seen in breast cancer
[72, 80], prostate cancer [81, 82], colon cancer [83], and other
cancers [79, 84–87], and increased caspase 9 was observed in
pancreatic cancer [87], glioblastoma [85], and several other
cancer types [84, 86].
3.1.3 Genistein treatment can decrease activation of Akt
and NF-κB
Akt proteins are serine/threonine kinases that act as master
regulators of cellular proliferation, protein synthesis, and
apoptosis. As these kinases are upstream of a wide variety of
other pathways that are involved in cell survival and
proliferation, derangements of these pathways are often
implicated in the development of a variety of cancer types.
Akt is able to inhibit Bad activity, which decreases the
chances of apoptosis [88, 89]. Additionally, Akt can activate
470 Cancer Metastasis Rev (2010) 29:465–482mTOR, which results in stimulation of protein synthesis and
cell growth [90]. Akt can also inhibit GSK-3β, which is an
inhibitor of cyclin D1, a protein critical for early cell cycle
progression [91]. Thus, activation of Akt in this context
results in increased stimulation of cell proliferation. Finally,
Akt activates Rho signaling, which results in increased cell
motility. Based on these combined results, Akt and its
associated signaling pathways have been attractive therapeu-
tic targets for inhibiting cancer growth and metastasis [92].
At concentrations similar to those used in studies on
cellular proliferation and apoptosis, genistein has been shown
to decrease phosphorylated-Akt in prostate cancer [82, 93],
breast cancer (both in vitro and in vivo)[ 94–96], colon
cancer [97], and several other cancer types [77, 98–100]. It
has been hypothesized that this inhibition of Akt is partially
responsible for the effects on cell proliferation that were
described in the previous two sections (reviewed in [65]).
Another major target of Akt is the NF-κB pathway.
Upon activation by an IκB kinase, NF-κB translocates into
the nucleus where it regulates gene expression. Many of its
target genes have antiapoptotic effects, such as Bcl-2, or
regulate the cell cycle, such as myc and cyclin D1 [50].
Inhibition of NF-κB by genistein has been observed in
prostate cancer [93, 101, 102], breast cancer [94], and other
cancers [98, 103] and may also partially explain the effects
of genistein on cell cycle progression and apoptosis.
3.2 Genistein can alter cell adhesion
Concurrent with the process of primary tumor growth,
cancer cells also acquire additional molecular aberrations
that allow them advance further in the metastatic process.
Decreased cell adhesion, or cell detachment, is an initial
step in this metastatic transformation. In order for cells to
move from their primary site, they must first detach from
both the neighboring cells as well as from the extracellular
matrix (ECM). In the literature, cell adhesion generally
refers to the attachment of the cells to the ECM, whereas
the process of cells adhering to one another is termed cell–
cell adhesion. In both instances, these processes are
mediated by transmembrane cell adhesion molecules.
Cell–cell adhesion is canonically mediated by the binding
of the cadherin family of proteins to each other, which is
known as homotypic binding. Cell adhesion to the ECM is
mediated by heterotypic binding, which involves two
different proteins binding to one another, in order to anchor
the cell. In epithelial cells, the major proteins involved in
heterotypic binding are the integrin family of proteins
[104]. Transmembrane integrin receptors are heterodimeric
complexes, composed of α and β integrin subunits. There are
at least eighteen α and eight β integrin isoforms, and the
combination of α/β integrin subtypes determines the specific
ECM protein to which each integrin binds. The expression of
specific integrin subtypes, such as α3β1a n dα6β1, has been
associated with invasive cancer [105–107] and has also been
implicated in genistein-mediated effects on adhesion. Integ-
rins anchor the cell by the binding of the extracellular
domain to the ECM proteins, while the integrin cytoplasmic
domain binds to the actin cytoskeleton [104, 108]. This
cytoplasmic domain connects to actin filaments via the
structural adapter proteins, talin and vinculin [109, 110]. The
associated macromolecular complex formed from these
protein interactions is termed a focal adhesion complex.
This complex provides a central location for cell signaling
proteins that are involved in cellular adhesion and cellular
migration, such as focal adhesion kinase (FAK), paxillin, and
Src. FAK is a downstream target of several growth factor
receptors, including epidermal growth factor receptor and
platelet-derived growth factor receptor, and upon activation
FAK recruits a variety of signaling factors that can regulate
cell adhesion and cell motility [111]. FAK therefore plays a
central role in integrin signaling, and many groups have
studied its ability to regulate cell adhesion, migration, and
invasion [112–114]. Increased FAK expression has been
reported in several different cancers and can lead to
decreased apoptosis and increased cell motility [115–119].
Our group has demonstrated that genistein increases
human prostate cancer cell adhesion both in vitro [120] and
in prostate cancer cells orthotopically implanted into mice
[121]. This indicates that genistein can act to inhibit cell
detachment, which is an early step in the metastatic
cascade. Genistein-mediated increases in cell adhesion are
time and concentration dependent and can be observed at
low nanomolar concentrations of genistein. Though the
exact pharmacologic mechanism by which genistein induces
changes in cell adhesion is not known, we have shown that
genistein increases FAK translocation to the focal adhesion
complexes [120]. FAK then forms a complex with β1
integrin, and this interaction restores polar β1 integrin
expression in cells that have lost integrin polarity [115, 120].
In other cancer types, genistein’s effects upon cell
adhesion have been less extensively investigated. Genistein
increases the adhesion of breast cancer [120, 122] and
melanoma cells [122] in vitro at submicromolar concen-
trations, similar to the findings for prostate cancer. In
contrast, genistein can inhibit the adhesion of hepatocarci-
noma cells and pancreatic cells in vitro [123, 124]. These
contrasting effects on cellular adhesion could stem from
differences in cell type or assay methodology. In particular,
changes in the type of ECM proteins and/or changes in the
timing of drug treatment can have profound effects on the
outcome of adhesion assays. Interestingly, studies that have
measured adhesion along with other motility-associated
parameters, such as migration and invasion, have shown
that genistein inhibits cell motility regardless of its effects
upon cell adhesion. Since adhesion is a kinetic process,
Cancer Metastasis Rev (2010) 29:465–482 471involving cyclical detachment and attachment of integrins,
it is possible that genistein is affecting the rate of focal
adhesion complex formations. This would also explain the
inconsistencies in genistein’s effect on cellular adhesion in
different cancer cell types. Genistein consistently inhibits
FAK activation in all of these studies, irrespective of its
effect upon adhesion [120, 123, 125]. Given FAK’sr o l ei n
regulating focal adhesion complex formation and turnover, it
is likely an important pharmacological target for genistein’s
effects upon adhesion.
3.3 Genistein can decrease the rate of cell migration
Once cells have detached from the ECM, they then acquire
the ability to increase their motility. Cell migration is an
important part of the metastatic cascade; it is necessary for
cells to move through the primary organ. However,
migration is a complex process that is poorly understood.
Awide variety of proteins that can alter cell migration have
been identified, but it is unclear how these are regulated in
the cell [126, 127]. Changes in focal adhesion complex
have been implicated to play a role in cell migration, as
FAK has been shown to increase this phenotype in Chinese
hamster ovary cells [112]. Despite preliminary studies,
however, migration still remains one of the least extensively
studied aspects of cancer metastasis.
Due to the limited study of this phenotype, the effects of
genistein on cellular migration have only been studied on a
limited basis. Studies have shown that genistein treatment
can decrease cell migration in rat prostate carcinoma cells
in a dose-dependent manner, over the noncytotoxic concen-
t r a t i o nr a n g eo f1t o1 0μM[ 124]. Over a similar
concentration range, genistein can inhibit the migration of
murine breast cancer and melanoma cells [122]. Importantly,
studies have demonstrated that genistein inhibits phosphory-
lation of FAK on Y387, which is necessary for increases in
cell migration [64]. These results imply that genistein’s
effects on both cell adhesion (see Section 3.2) and cell
migration are in part regulated by its ability to inhibit
activation of FAK. However, the exact mechanism by which
genistein can alter these processes is not known.
3.4 Genistein can decrease matrix metalloproteinase
expression
The process of cell invasion is a combination of in cell
migration with concurrent degradation of the surrounding
ECM. This degradation of ECM proteins is mediated
largely by matrix metalloproteinases (MMPs) [128]. MMPs
constitute a family of zinc endopeptidases that cleave ECM
proteins, thereby contributing to a variety of functions
involved with normal homeostatic cell movement and
tissue remodeling. MMPs have been categorized based
upon the proteins that they degrade. These classifications
include: collagenases, gelatinases, stromelysins, matrilysins,
and membrane-type MMPs [129]. MMPs play a role in
normal cell growth and division, as cells are continually
cleaving and rebuilding the surrounding extracellular matrix
as they proliferate. However, MMPs also play a role in
aberrant cell growth and tumor formation, since they provide
space for the tumor to grow and release various growth
factors that drive tumor proliferation. This dual function
makes targeting these molecules difficult, as these proteins
are promoted in cancer development but are also critical in
normal homeostatic processes. Therefore, global inhibition of
MMPs also impacts basic and critical cellular process. This
has created a difficulty in targeting MMPs therapeutically, as
small-molecule inhibitors designed to bind the MMP active
siteare not abletoeffectively discriminatebetween individual
MMP subtypes. For this reason, when tested in clinical trials,
MMP inhibitors have induced general toxicity, such as
muscular and skeletal joint pain, thereby preventing their
further clinical development [130].
MMP-2, along with MMP-9, makes up the gelatinase
family of MMPs. These proteins degrade a variety of ECM
proteins, including type IV collagen [128]. This is
significant as the basement membrane is made up primarily
of type IV collagen [131], although it also contains
laminins, osteonectin, heparin proteoglycans, and enactin
[126, 132]. These extracellular membrane proteins are the
first to be cleaved during the invasive stage of cancer
progression. Increased expression of MMP-2 has been
shown to predict a poor prognosis in a variety of cancers,
including ovarian, pancreatic, prostate, and colorectal
cancer (reviewed in [128]). In addition, MMP-2-deficient
mice show decreased rates of cancer progression and
angiogenesis in melanoma cells [133].
Our group has shown that genistein is able to decrease
MMP-2 expression in a panel of human prostate cancer cell
lines ranging from primary noncancerous cells to estab-
lished metastatic variant cells, although little to no effect on
MMP-9 was observed in this study at [134]. Effects were
observed with genistein concentrations down to 10 nM.
Reduction of MMP-2 by genistein treatment has also been
confirmed by other groups in prostate cancer [135], breast
cancer [136, 137], and glioblastoma cell lines [138].
Decreased expression of MMP-7 and MMP-9 has been in
observed in breast cancer lines treated with genistein [136,
137], and decreased expression MMP-9 has also been
observed in prostate cancer [139], glioblastoma [138], and
pancreatic cancer [140] in vitro. In melanoma, breast, and
prostate cancer cells, treatment with genistein decreases
general zymographic activity, which is a measure of MMP
activity [122, 141]. These combined studies demonstrate
that genistein can selectively inhibit the production of
individual MMPs, which could have significant impact on a
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tissue.
3.5 Mechanisms of genistein-mediated decrease in cell
invasion
Cell invasion represents a critical characteristic of the
metastatic phenotype. In order for invasion to occur physio-
logically, cells must invade through the basement membrane,
through the primary organ, and through the distant organ to
which they eventually metastasize. Cells that are more
phenotypically invasive, as well as those that show molecular
alterations characteristic of invasive potential, show a greater
propensity to metastasize [50].
OurgrouphasshownthatgenisteinisabletoinhibitMMP-
2 production in multiple studies, as described in Section 3.4.
Through an additional series of studies, we have elucidated a
key signaling pathway in human prostate cancer cells that
plays a role in regulating cell invasion and metastasis and is
also inhibited at genistein concentrations as low as 10 nM
[134, 142–144]. This pathway is as follows: TGF-
β→MEK4→p38 MAPK→MAPKAPK2→HSP27→MMP-
2→invasion, where TGF-β is transforming growth factor β,
MEK4 is mitogen-activated protein kinase kinase 4, p38
MAPK is p38 mitogen-activated protein kinase, MAP-
KAPK2 is mitogen-activated protein kinase-activated protein
kinase 2, and HSP27 is heat shock protein 27 (see Fig. 4).
Many of the proteins in this pathway have been linked to
cancer progression and metastasis. Studies have shown that
MEK4 is a key tyrosine/threonine kinase that is upregulated
in advanced human and mouse prostate cancer progression
[145] and can increase invasion of breast and pancreatic cells
[146]. We have demonstrated that genistein directly binds to
and inhibits the kinase activity of MEK4, thereby inhibiting
the production of MMP-2 and decreasing cellular invasion
[143]. p38 MAPK mediates a variety of cellular processes,
ranging from proliferation and cell survival to invasion and
metastasis (reviewed in [147]). HSP27 is upregulated in
human prostate cancer progression [148] and regulates the
structure and function of the actin cytoskeleton, which has
important consequences for cell motility [149]. When
dephosphorylated, HSP27 acts as an actin capping protein
and thus inhibits actin polymerization [150, 151]. However,
when phosphorylated, HSP27 induces increased F-actin
formation [152, 153], increased cell migration [154, 155],
and increased cell invasion [144].
The MEK4 pathway has also been shown to crosstalk with
the endoglin signaling pathway via the Smad family of
transcription factors [156]. We have also shown that the
endoglin pathway suppresses human prostate cancer cell
invasion and that genistein activates endoglin pathway
signaling [157–159]. Endoglin is an accessory TGF-β
superfamily receptor that is lost during prostate cancer
progression [157]. Endoglin signaling in prostate cancer
was shown by our group to be dependent upon the type I
TGF-β superfamily receptor, ALK-2. Endoglin’ss u p p r e s -
Fig. 4 Genistein inhibits critical
pathways in cancer invasion.
Our group has demonstrated that
genistein can specifically target
MEK4. This inhibition results in
inactivation of the MEK4 path-
way, decreased MMP-2 produc-
tion, and decreased cell
invasion. Genistein also acti-
vates Smad1, which is activated
by the endoglin signaling path-
way, and causes decreased cell
invasion. Additionally, genistein
inhibits FAK activation, result-
ing in increased cell adhesion.
At this time, it is unclear
whether the activation of Smad1
and FAK are due to genistein’s
inhibition of MEK4 or via a
different signaling mechanism
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activation of the transcription factor Smad1 [158] (see
Fig. 4). Ultimately, the state of cellular invasion is regulated
by the ratio of Smad1 to Smad3. Smad1 is activated by the
endoglin/ALK-2 signaling pathway and acts to suppress
invasion. In contrast, Smad3 is activated by the TGF-β/
ALK-5 signaling pathway, also known as the canonical
TGF-β signaling pathway, and acts to increase invasion.
Genistein is able to act on both branches of this pathway.
Genistein acts to inhibit the canonical TGF-β pathway at the
levels of Smad3 by virtue of its ability to inhibit MEK4. This
is due to the fact that p38 MAPK, which is downstream of
MEK4, activates Smad3 through signaling crosstalk [156].
Conversely, genistein can activate Smad1 in a manner that is
dependent on ALK-2 kinase activity, but that is independent
of endoglin [159]. This is important, as genistein can
therapeutically compensate for endoglin loss, which occurs
in prostate cancer progression. Therefore, these two linked
signaling pathways have been identified as important
regulators of human prostate cancer cell invasion, and
genistein induces anti-invasive effects on both pathways.
Other groups have demonstrated that genistein sup-
presses invasion of a variety of prostate cancer cell lines
through mechanisms other than inhibition of TGF-β
signaling [139, 160, 161]. In androgen-responsive human
prostate cancer cells, low micromolar concentrations of
genistein significantly inhibited invasion [161]. This study
proposed that genistein acted by causing a reversion of the
epithelial to mesenchymal transition, or EMT. The EMT is
a process by which cells revert from a more differentiated,
epithelial state to a more undifferentiated, or mesenchymal,
state, which involves the perturbation of a variety of
proteins involved in cellular differentiation. This process
commonly occurs as cancer cells progress to a more
advanced stage. In this study, genistein caused a reversion
of this EMT phenotype by increasing levels of E-cadherin, a
membrane protein that is associated with increased cell–cell
adhesion and reduced invasive potential. Genistein also
decreased the levels of vimentin, a protein that is typically
associated with a mesenchymal, or invasive, state (see
Section 3.2).
Multiple groups have also demonstrated that genistein
can inhibit invasion of breast cancer cells [137, 162–164].
In one study, the authors proposed that decreased invasion
with genistein treatment was a result of decreased production
of MMPs (see Section 3.4), although an exact molecular
target was not discussed [137]. A second study demonstrated
that genistein is able to downregulate the levels of the
chemokine receptors CXCR4 and CXCL12 when the breast
cancer cells were treated with low micromolar concentrations
of genistein [162]. These receptors direct the homing of
primary cancer cells to a metastatic site and can also alter
cellular adhesion.
Genistein can also decrease cell invasion in other cancers
such as pancreatic cancer [140] and colon cancer [165]. In
pancreatic cancer, the protein Forkhead box protein M1
(FoxM1), which is normally associated with cell cycle
progression through the G2/M-phase checkpoint, was
implicated as a target of genistein action at 50 to 100 μM
[140]. This inhibition of FoxM1 resulted in a decrease in
MMP-9, as well as decreases in proteins that regulate the
cell cycle and angiogenesis. Similarly, genistein was shown
to inhibit invasion of colon cancer at similar concentrations
to those used in the studies on pancreatic cancer, although
the effects were thought to be a result of genistein’s
antioxidant properties (see Section 2.1), rather than inhibition
of any specific proteins [165].
Taken together, the above studies demonstrate that genis-
tein is capable of inhibiting invasion through a variety of
mechanisms in multiple cell types. In human prostate cancer,
MEK4 is a key pharmacologic target of genistein’sa n t i -
invasion action. However, for other cancer types, it is not yet
known whether genistein’s effects stem from regulation of the
same or a different pharmacologic target. Further, it is not
clear whethergenisteinisactinguponmultiplepharmacologic
targets or whether it is acting upon a single target which then
regulates a variety of other pathways. This situation could be
clinically relevant, as cancer cells contain multiple molecular
abnormalities that require therapeutic correction in order to
restore the desired phenotype. Therefore, while these studies
demonstrate thatgenistein has a multitude ofeffects oncancer
invasion, they also suggest that genistein represents a
promising multitarget therapeutic agent.
4 Genistein’s effects upon metastasis in preclinical
animal models
As an extension of the in vitro studies discussed in
Section 4, our group has demonstrated that genistein can
inhibit prostate cancer metastasis in mice [121]. In this
study, human prostate cancer cells were implanted into the
prostate glands of mice fed with 0, 100, or 250 mg
genistein per kilogram of soy-free chow. The human
prostate cancer cells in this study were metastatic variant
PC3-M cells, which are androgen and estrogen receptor
negative and hormonally unresponsive. The genistein
treatment regime yielded plasma concentrations of total
genistein of 0, 290, and 1,307 nM, respectively. As only
10% of circulating genistein is in the free, unconjugated
form, free plasma concentrations of genistein were estimated
to be 0, 29, and 131 nM, respectively. These concentrations
correspond to those measured in humans who subsist on a
soy-based diet (see Section 2.2). Genistein treatment signif-
icantly decreased the formation of distant soft tissue
metastasis in a dose-dependent fashion. There was no effect
474 Cancer Metastasis Rev (2010) 29:465–482upon primary tumor growth, which is consistent with
genistein’s primary role as an inhibitor of metastasis, rather
than a cytotoxic agent. Analysis of primary tumor tissue
indicated that genistein was inhibiting the detachment of
prostate cancer cells, as assessed by quantitative image
analysis. Importantly, genistein decreased phosphorylation of
both p38 MAPK and HSP27 in tumor tissue, consistent with
inhibition of MEK4. Further, genistein treatment decreased
phosphorylation of FAK, but this trend was not statistically
significant.
Other groups have also demonstrated that consumption
of soy or genistein can inhibit human prostate cancer
progression or metastasis in vivo [166]. In one report, the
authors used hormonally responsive LNCaP cells and
investigated three different soy-based dietary preparations.
Each preparation decreased tumor weight in a statistically
significant manner. However, since each of the preparations
also decreased serum androgen levels, effects on tumor
growth were likely mediated through primary effects on
androgen concentrations. Furthermore, mice that were fed
genistin, or the glycosylated form of genistein, did not have
decreased metastasis, while mice fed soy phytochemical
concentrate, which is high in genistein, did have decreased
metastasis. While it would be expected that genistein would
readily be converted to genistein, these findings call this
assumption into question. Therefore, the type of preparation
appears to have a significant impact on outcome. Similarly,
genistein has alsobeenshown todecreasecancerproliferation
in a rat model of spontaneous prostate cancer, which was
constructed using a Simian Virus-40 T-antigen targeted
probasin promoter [167]. In this study, a dose of 250 mg
genistein per kilogram chow (which gave to a blood
concentration of 2,160 nM of total genistein) suppressed
the development of prostate cancer, although a dose of
83 mg genistein per kilogram was not effective. Treatment
with genistein caused decreased cell proliferation and
increased apoptosis in the prostate, as well as decreased
expression of insulin-like growth factor 1 and steroid
receptor coactivator 3 proteins, which have been implicated
in cell invasion and metastasis. Finally, a third group has
reported that genistein decreased cancer progression in a
murine model of prostate cancer that involved crosses
between TRAMP and C57BL/6 nontransgenic mice [160,
168, 169]. Interestingly, genistein increased cancer progres-
sion when TRAMP and FVB crosses were used [139]. FVB
and C57BL/6 mice have established genetic background
differences that can affect a wide variety of biological and
therapeutic response profiles [170], and these differences are
likely responsible for the differential outcomes observed
with genistein in these and other model systems.
Genistein has also been extensively studied in mouse
modelsofbreastcancer.However,genistein’sweakestrogenic
activity (see Section 2.1) has been the central focus of these
studies, as breast cancer is known to be hormonally
responsive. These studies indicate that the effect of genistein
upon breast cancer is dependent upon the nature of the
estrogenic environment in which the study is conducted. If
endogenous estrogen is low, genistein can bind the ER
receptor and exert progrowth effects upon responsive
systems. If endogenous estrogen is high and potent, genistein
can act as a competitor to estrogen and thus antagonize this
hormone’s progrowth effects (reviewed in [171]). Therefore,
while genistein has shown promise as an anticancer agent for
breast cancer, the results are much more complex and
dependent on hormone levels than those for prostate cancer.
In non-estrogen-dependent cancer types, genistein has
shown strong promise as an inhibitor of metastasis in mice.
Soy concentrate and genistin both inhibited the growth of
human bladder cancer cells in mice, and soy concentrate
inhibitedformationofmetastasis[79]. In an orthotopic model
of pancreatic cancer in mice, genistein induced apoptosis of
the primarytumor and inhibitedmetastasis[87]. Additionally,
another group has shown that genistein reduced metastasis of
murine colon cancer cells to the lungs in a murine model
[165]. In an azoxymethane-induced intestinal adenocarcino-
ma model in Wistar rats, genistein had no effect upon
primary tumors but inhibited metastasis [172]. Similarly,
genistein also decreased primary tumor growth as well as the
formation of metastasis in an orthotopic murine model of
human hepatocellular carcinoma cells [123]. Therefore, these
examples demonstrate that genistein consistently reduces the
formation of metastasis in a variety of tumor types, while it
has varied effects on the primary tumor.
5 Prospective studies of genistein in humans
Most clinical trials of genistein have examined dose ranges
that are similar to those consumed in the diet. To date, both
phase I and phase II clinical trials have been performed
with doses of genistein that were chosen to approximate the
dietary consumption level of regular soy consumers, which
ranges from 0.3 to 1 mg per kg body weight per day [29–
41]. Phase I trials were designed to characterize the toxicity
and pharmacology of genistein in order to better understand
its metabolism and safety in the body, while phase II trials
were designed to test genistein’s efficacy in humans.
In order to better understand the pharmacokinetic
parameters of genistein in humans, we have performed an
initial phase I single-dose study of genistein in a cohort of
men with prostate cancer [173]. In this study, we examined
doses of 2–8 mg genistein per kilogram body weight. The
2 mg per kg dose was chosen to correspond with an amount
equivalent to two to seven times the average daily genistein
consumption, while the 8 mg per kg dose corresponded to
eight to 27 times the average daily consumption. Genistein
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peak blood concentrations of total genistein ranged from 4.3
to 16.3 μM, and the peak concentrations of free genistein
ranged from 66 to 170 nM, indicating that 90% of blood
genistein was conjugated (consistent with the population-
based studies, see Section 2.2). The half-life of genistein was
15–22 h, and its clearance was not altered by body mass,
indicating that dosing does not need to be calculated based
upon weight (i.e., fixed amounts of drug can be administered
to humans). Asimilarstudyfocuseduponacohortofyounger
healthy men and reported similar findings, with the exception
that genistein showed a half-life of only 9 h [174]. Another
study examined doses of 4–8 mg genistein per kilogram
given daily for 3 months to a cohort of men with prostate
cancer [175]. This study showed a similar pharmacokinetic
profile for genistein and, importantly, demonstrated that
pharmacokinetic parameters were not affected after chronic
dosing. Interestingly, this study also reported estrogen-
related side effects, such as breast tenderness and flushing.
However, the men in the study cohort were also on
antiandrogen hormone therapy for prostate cancer, and these
side effects are commonly associated with this therapy.
Therefore, it is unclear whether these side effects were due to
genistein or to the hormone therapy. These side effects were
not seen in any of the other studies that were performed at
similar dose levels, suggesting that genistein does not induce
estrogenic side effects in men, at least with the doses and
treatment times examined to date.
Phase I trials have also been conducted in a cohort of
healthy postmenopausal women, where doses of 2–16 mg
genistein per kilogram were examined [176]. Breast tender-
ness, an indicator of estrogen action, was reported in this
study, though it was unclear whether it was due to genistein
treatment. Pharmacokinetics for genistein were similar to
those reported by the same group in a cohort of healthy men,
suggesting that administration of genistein to varied popula-
tions results in a consistent pharmacokinetic profile [174].
In addition to these phase I studies, several phase II studies
of genistein in subjects with prostate cancer have also been
reported. In a recent study by our group, subjects were
randomized to treatment with 2 mg genistein per kilogram
body weight versus no treatment prior to undergoing radical
prostatectomy for localized prostate cancer [143]. After
treatment, histologically normal prostate epithelial cells were
then selectively removed from intact prostate tissue by laser
capture microdissection. These cells, present within a
prostate gland that also harbors prostate cancer, represent
an “at-risk” target cell type and are therefore a viable target
for a compound that inhibits conversion to an invasive
phenotype. MMP-2 transcript levels were evaluated in these
cells by qRT/PCR, and it was shown that genistein decreased
MMP-2 gene expression to 24% of the level seen in control
subjects. Blood concentrations of free genistein were
approximately 140 nM in the genistein-treated cohorts, while
the levels in the control group were below detection. This
study demonstrated for the first time that it is possible to
inhibit prometastatic processes in humans through a targeted
therapeuticintervention[143]. Findings from this prospective
study are consistent with epidemiological studies that link
genisteinconsumptiontodecreasedprostatecancermetastasis
and decreased mortality from prostate cancer. It will be
important for future studies to evaluate the ability of genistein
to inhibit prostate cancer metastasis in the context of a
prospective randomized study.
In another phase II trial, subjects with progressive prostate
cancer were treated with soy milk three times daily for
12 months, which roughly equated to a genistein concentra-
tion of 1 mg genistein per kilogram per day [177]. This
treatment regimen gave a median blood concentration of free
genistein of 44 nM. Soy milk treatment decreased the rate of
increase of serum prostate-specific antigen (PSA) when
compared to the rate of increase of PSA that was seen in
subjects prior to entering the study. PSA is used clinically to
track prostate cancer growth in humans, and in normal cancer
progression, the rate of PSA increase tends to accelerate with
time. Therefore, the factthatthistreatment regimeslowedthis
process even as time progressed represents a significant
accomplishment. Finally, a third phase II study of genistein in
men with various stages of prostate cancer was performed by
administering soy extract at an approximate dose of 6 mg
genistein per kilogram per day for 6 months [178]. This
therapy was similarly well tolerated, as less than 10% of
participantsexperiencedmilddiarrhea,and17%ofparticipants
experienced a decrease in their PSA levels.
Clinical trials are now increasingly testing genistein in
combination with other agents. The primary focus of these
studies is typically on advanced cancer, with the primary
goal of identifying combination therapies that are able to
effectively kill cancer cells. One such study examined
genistein in combination with gemcitabine in subjects with
advanced pancreaticadenocarcinoma[179], while another has
examined the combination of genistein and lycopene in
subjects with recurring prostate cancer [180]. While no
definitive activity was observed in either study, these
investigations are still at the early stages. In addition, several
phase II trials of genistein in breast, prostate, and pancreatic
cancer are ongoing, as listed in the NIH Clinical Trials
database. With the early promise of genistein as a single-
agent therapeutic in prostate cancer, it will be important to
determine if this effect is translatable to other cancers.
6 Conclusion
Genistein is a biologically important isoflavone that is
found in high amounts in soy products. This small
476 Cancer Metastasis Rev (2010) 29:465–482compound has garnered a great deal of attention in the field
of oncology research, as it exerts a wide range of biological
effects of direct relevance to cancer. In particular, genistein
has proven to be a valuable tool for the inhibition of
cancer metastasis, exerting effects on both the initial steps
of primary tumor growth as well as the later steps of the
metastatic cascade. The concentration at which genistein is
used is a critical determinant of the range of targets that it
affects and the cellular phenotypes that result from
treatment. At concentrations of genistein near the micro-
molar range, which have been achieved in prospective
phase I studies, genistein exhibits significant inhibition of
tumor growth. This inhibition of proliferation has been
linked to genistein’s interaction with a variety of different
protein classes, including cell cycle regulators, proapop-
totic and antiapoptotic proteins, and the Akt/NF-κBf a m i l y
of proteins. Additional preclinical studies have indicated
that inhibition of the later steps of the metastatic cascade
may be an important biological effect of genistein at low
nanomolar concentrations, which are achieved through
dietary consumption. Genistein has been shown to exert
inhibitory effects on targets that are involved in almost
every step of the metastatic cascade, including FAK,
integrins, TGF-β signaling molecules, and MMPs, which
together are critical to the processes of cell adhesion and
invasion. Early positive clinical trial studies have corrob-
orated these preclinical findings, as subjects administered
genistein show decreased markers of advanced metastatic
disease, such as MMP-2 and PSA. These preliminary
evaluations will need to be pursued by larger confirmatory
prospective clinical studies, but the findings from ongoing
trials have already provided critical information about the
clinical importance of these mechanisms. Overall, genis-
tein represents a powerful tool for understanding cancer
development and holds great promise as a therapeutic
inhibitor of metastasis in a variety of cancer types.
Furthermore, findings to date s u g g e s tt h a tg e n i s t e i nh a s
the potential to have a high clinical impact, and it is clear
that expanding our knowledge of this important natural
product will lead to novel future developments in the field
of cancer treatment.
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